Aspirin Dosing for Cardiovascular Disease Prevention

Introduction to Aspirin Dosing

The American Diabetes Association recommends 75-162 mg/day as the optimal maintenance dose for aspirin therapy in patients with established cardiovascular disease 1, 2, 3, 4
The American College of Chest Physicians found no convincing evidence that higher doses are more effective than lower doses for reducing serious vascular events 5, 6

The ADAPTABLE trial found no significant difference in major bleeding between 81mg and 325mg daily aspirin in over 15,000 patients with established cardiovascular disease 1, 2, 3, 4
The ADAPTABLE trial also found no significant difference in cardiovascular events between 81mg and 325mg daily aspirin in patients with established cardiovascular disease 1, 2, 3, 4

Gastrointestinal side effects are clearly dose-dependent, with higher doses causing more GI symptoms 5
The ARRIVE trial showed gastrointestinal bleeding in 0.97% with aspirin versus 0.46% with placebo (HR 2.11) 1
The ASPREE trial demonstrated major hemorrhage rates of 8.6 versus 6.2 events per 1,000 person-years with aspirin versus placebo (HR 1.38) 1

The World Stroke Organization recommends aspirin 81-325mg daily for secondary prevention, with lower doses preferred 7
The American College of Chest Physicians recommends 75-162mg daily as the optimal maintenance dose for aspirin therapy 5, 6

For maintenance therapy, use 81mg daily as the preferred dose to minimize bleeding risk while maintaining efficacy 1, 2, 3, 4
For acute coronary syndromes, a loading dose of 162-325mg non-enteric coated aspirin should be given immediately, followed by 81mg daily maintenance 8, 9, 10

Any aspirin dose carries approximately 5 excess bleeding events per 1,000 patients per year in real-world settings 1
For patients with ASCVD risk >1% per year, the number of events prevented equals the number of bleeding episodes induced 1

For acute situations, such as myocardial infarction, unstable angina, or percutaneous coronary intervention, a loading dose of 162-325 mg of non-enteric coated aspirin is recommended to achieve rapid platelet inhibition, as suggested by the American Heart Association 11, 12
The European Society of Cardiology recommends a maintenance dose of 75-100 mg daily for patients with prior myocardial infarction or revascularization, as stated in the 2024 ESC guidelines 13
For primary prevention, a dose of 75-100 mg daily is recommended, as suggested by the American Academy of Family Physicians 14
The American College of Cardiology recommends a maintenance dose of 81-325 mg daily post-percutaneous coronary intervention, but lower doses within this range are preferred, as stated in the 2014 AHA/ACC guidelines 11

For acute coronary syndrome or acute myocardial infarction, a loading dose of 162-325 mg is recommended, followed by a maintenance dose of 75-100 mg daily, as suggested by the American Heart Association 11, 12
For post-myocardial infarction or post-revascularization maintenance, a dose of 75-100 mg daily is recommended, as stated in the 2024 ESC guidelines 13
For chronic stable coronary disease, a maintenance dose of 75-100 mg daily is recommended, as stated in the 2024 ESC guidelines 13

The 2004 STEMI guidelines recommended a dose of 75-162 mg daily for indefinite post-myocardial infarction therapy, as stated in the Journal of the American College of Cardiology 15
The European Heart Journal suggests that contemporary evidence strongly favors the lower end of the dosing range for maintenance therapy, as stated in the 2024 European Society of Cardiology guidelines 13

The American College of Cardiology recommends 75-100mg daily for maintenance therapy after the initial 30-day period following acute coronary syndrome 16
The American College of Cardiology and American Heart Association suggest a loading dose of 162-325mg non-enteric coated aspirin for acute coronary syndromes, myocardial infarction, or before percutaneous coronary intervention 16
After carotid endarterectomy, 81-325mg daily is acceptable initially, but lower doses within this range are preferred for long-term use, as recommended by the American College of Cardiology and American Heart Association 17, 18
Following the acute phase, transition to 75-100mg daily for maintenance therapy, as recommended by the American College of Cardiology and American Heart Association 16

For acute presentation, give 162-325mg non-enteric coated aspirin immediately and continue for up to 30 days post-PCI or acute event, as recommended by the American College of Cardiology and American Heart Association 16
For maintenance therapy, transition to 75-100mg daily indefinitely, as recommended by the American College of Cardiology and American Heart Association 16
When using ticagrelor as the P2Y12 inhibitor, aspirin doses must not exceed 100mg daily due to reduced efficacy observed with higher doses in the PLATO trial, as recommended by the American College of Cardiology and American Heart Association 16

The 2011 ACC/AHA carotid disease guidelines recommend 81-325mg with preference for lower doses for long-term prophylaxis, as stated by the American College of Cardiology and American Heart Association 17, 18
The 2014 AHA/ACC NSTE-ACS guidelines specify 81-325mg post-PCI, with 81mg preferred long-term, as recommended by the American Heart Association and American College of Cardiology 19
The 2025 ACC/AHA acute coronary syndrome guidelines explicitly state 75-100mg for maintenance therapy, as recommended by the American College of Cardiology and American Heart Association 16
The American College of Chest Physicians recommends 75-100mg as optimal maintenance dose, as stated by the American College of Chest Physicians 20